(Q36348627)

13 August 2017

1 reference

title

Omalizumab: a monoclonal anti-IgE antibody (English)

1 reference

13 August 2017

Paul P Belliveau

1

1 reference

13 August 2017

publication date

27 January 2005

1 reference

MedGenMed : Medscape general medicine

13 August 2017

published in

1 reference

13 August 2017

volume

7

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

27

1 reference

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insect stings

13 August 2017

cites work

1 reference

12 December 2020

Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma

1 reference

12 December 2020

Metabolic properties of IgG subclasses in man

1 reference

12 December 2020

The role of ige in the immune response to neoplasia: A review

1 reference

12 December 2020

IgE receptors on human basophils. Relationship to serum IgE concentration

1 reference

12 December 2020

Association of asthma with serum IgE levels and skin-test reactivity to allergens

1 reference

12 December 2020

Monoclonal antibodies defining epitopes on human IgE

1 reference

12 December 2020

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

1 reference

12 December 2020

Fine specificity of the IgE interaction with the low and high affinity Fc receptor.

1 reference

12 December 2020

Humanization of an antibody directed against IgE

1 reference

12 December 2020

The human IgE network

1 reference

12 December 2020

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

12 December 2020

CD23/IgE-mediated regulation of the specific antibody response in vivo.

1 reference

12 December 2020

The binding site on human immunoglobulin E for its high affinity receptor.

1 reference

12 December 2020

Human FcERI-IgG and humanized anti-IgE monoclonal antibody MaE11 block passive sensitization of human and rhesus monkey lung

1 reference

12 December 2020

Inhibition of allergic reactions with antibodies to IgE

1 reference

12 December 2020

Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE.

1 reference

12 December 2020

A conformational rearrangement upon binding of IgE to its high affinity receptor

1 reference

12 December 2020

Rhinitis and asthma: evidence for respiratory system integration

1 reference

12 December 2020

Omalizumab is effective in the long-term control of severe allergic asthma

1 reference

12 December 2020

Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis

1 reference

12 December 2020

Binding of cynomolgus monkey IgE to a humanized anti-human IgE antibody and human high affinity IgE receptor

1 reference

12 December 2020

Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys

1 reference

12 December 2020

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

1 reference

12 December 2020

Antigen presentation by memory B cells: the sting is in the tail.

1 reference

12 December 2020

Expression of high-affinity IgE receptors (FcϵRI) on peripheral blood basophils, monocytes, and eosinophils in atopic and nonatopic subjects: Relationship to total serum IgE concentrations

1 reference

12 December 2020

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

12 December 2020

Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response

1 reference

12 December 2020

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis

1 reference

12 December 2020

In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody

1 reference

12 December 2020

Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy?

1 reference

12 December 2020

The expression of murine B cell CD23, in vivo, is regulated by its ligand, IgE

1 reference

12 December 2020

Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo

1 reference

12 December 2020

How much asthma is really attributable to atopy?

1 reference

12 December 2020

IgE in asthma and atopy: cellular and molecular connections

1 reference

12 December 2020

Pathophysiology of the inflammatory response

1 reference

12 December 2020

The pharmacological basis of anti-IgE therapy

1 reference

12 December 2020

Therapeutic monoclonal antibodies

1 reference

12 December 2020

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

1 reference

12 December 2020

Immunoglobulin E: importance in parasitic infections and hypersensitivity responses

1 reference

12 December 2020

Trends in the cost of illness for asthma in the United States, 1985-1994

1 reference

12 December 2020

Allergy and allergic diseases. First of two parts

1 reference

12 December 2020

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

1 reference

12 December 2020

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

1 reference

12 December 2020

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

1 reference

12 December 2020

Molecular and cellular mechanisms of allergic disease

1 reference

12 December 2020

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

1 reference

12 December 2020

1 reference

12 December 2020

Anti-immunoglobulin E (omalizumab) therapy in allergic asthma

1 reference

12 December 2020

Allergic rhinitis and its impact on asthma

1 reference

12 December 2020

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

1 reference

12 December 2020

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

1 reference

12 December 2020

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

1 reference

12 December 2020

The burden of allergic rhinitis: beyond dollars and cents

1 reference

12 December 2020

The effect of omalizumab on nasal allergic inflammation.

1 reference

12 December 2020

Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma

1 reference

12 December 2020

Omalizumab and the immune system: an overview of preclinical and clinical data.

1 reference

12 December 2020

Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells

1 reference

12 December 2020

Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25

1 reference

12 December 2020

Omalizumab improves asthma-related quality of life in children with allergic asthma

1 reference

12 December 2020

The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis

1 reference

12 December 2020

Surveillance for asthma--United States, 1980-1999.

1 reference

12 December 2020

The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma

1 reference

12 December 2020

Is there a role for treatment of asthma with omalizumab?

1 reference

12 December 2020

Self-reported asthma and health-related quality of life: findings from the behavioral risk factor surveillance system.

1 reference

12 December 2020

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.

1 reference

12 December 2020

National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics--2002

1 reference

12 December 2020

Omalizumab (Xolair) improves quality of life in adult patients with allergic asthma: a review

1 reference

12 December 2020

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma

1 reference

12 December 2020

1 reference

12 December 2020

Effect of anti-IgE therapy in patients with peanut allergy

1 reference

12 December 2020

Evidence for a differential expression of the FcepsilonRIgamma chain in dendritic cells of atopic and nonatopic donors

1 reference

12 December 2020

Allergic rhinitis: broader disease effects and implications for management

1 reference

12 December 2020

Immunological and clinical changes in allergic asthmatics following treatment with omalizumab

1 reference

12 December 2020

What proportion of rhinitis symptoms is attributable to atopy?

1 reference

12 December 2020

Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma

1 reference

12 December 2020

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

1 reference

12 December 2020

Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis

1 reference

12 December 2020

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

1 reference

12 December 2020

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

1 reference

12 December 2020

Omalizumab inhibits allergen challenge-induced nasal response

1 reference

12 December 2020

Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma

1 reference

12 December 2020

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

1 reference

12 December 2020

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

1 reference

12 December 2020

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.

1 reference

12 December 2020

Identifiers

1 reference